Increased plasma follistatin levels in T2DM patients (Hansen et al., 2013; Sylow et al., 2020)Higher hepatic follistatin expression in MASLD patients (Tong et al., 2022)Moderate increase in plasma follistatin levels in obese patients (Maïmoun et al., 2020). The gene discussed is FST; the disease is metabolic dysfunction-associated steatotic liver disease.